EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE
Myeloma Patients Europe (MPE) is seeking research grant applications, for funding of up to 100k €, on a project exploring shared-decision making in myeloma. If you are interested, please read the information below and complete…
As bortezomib, an anti-myeloma medicine, is licensed as both an intravenous (IV – through the vein via a drip) and subcutaneous medicine (through the skin, via an injection), the European Medicines Agency (EMA) recently conducted…
Myeloma Patients Europe (MPE) is running a survey for European myeloma patients to understand their quality of life and how this is impacted by treatment side-effects.
A coalition of 60 patient advocates, healthcare professionals and scientists (including 3 Nobel Prize winners) from 20 European countries have come together to publish a blueprint for improving cancer outcomes and achieving better quality of…